Janssen/MeiraGTx sight loss gene therapy hits targets
Interim six-month data of RPGR gene therapy shows significant vision improvement in patients with X-linked retinitis pigmentosa
Read More
Tag: AAV-RPGR
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
